Physician profile
Sharon Johnson
NPI 1861697906
$2,978.58
in general payments reported to CMS, 2019-2025
25 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,880 · 2022: $389 · 2023: $142 · 2024: $35.52 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $999.26 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $344.71 | 2021-2025 | |
| Abbvie INC. | $320.23 | 2021-2025 | |
| Novo Nordisk INC | $179.44 | 2021-2022 | |
| Amgen INC. | $175.80 | 2021-2023 | Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $150.19 | 2021-2022 | |
| Eisai INC. | $146.52 | 2021 | |
| Lilly USA, LLC | $144.14 | 2021 | |
| Abbott Laboratories | $54.97 | 2021-2022 | |
| Astellas Pharma US INC | $49.45 | 2025 | Vyloy |
| Janssen Pharmaceuticals, INC | $48.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $45.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $40.20 | 2021-2025 | Zoryve |
| Allergan, INC. | $33.19 | 2021 | |
| Medtronic, INC. | $31.98 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.65 | 2021 | |
| Glaxosmithkline, LLC. | $30.48 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $23.67 | 2021-2022 | |
| Gilead Sciences, INC. | $22.77 | 2025 | |
| Radius Health, INC. | $22.68 | 2025 | Tymlos |
| Optinose US, INC. | $19.66 | 2021 | |
| Aveo Pharmaceuticals, INC. | $19.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2021 | |
| Merck Sharp & Dohme LLC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.